AI QUANT RESEARCH · INDIAN EQUITIES
Research any NSE stock in seconds
AI-generated deep research, factor scores and backtests across 2,000+ listed companies.
⌕
TRENDING
PASUPTAC+17.41%
BECTORFOOD+14.41%
WOCKPHARMA+14.04%
WELCORP+14.04%
ATHERENERG+13.59%
DIAMONDYD+13.42%
Top-rated by ftInvstr Score
daily recompute · live prices
MAJESA
85
MAJESAUT
Real Estate
₹338.90
+0.8%
Majestic Auto (MAJESAUT) registered a TTM PE of 4.06 and a PB ratio of 0.5, significantly undervalued relative to its book value of ₹681.41. The company boasts an impressive profit margin of 184.94%, despite its small market capitalization of ₹352.0 Cr.
GATECH
84
GATECH
Financial Services
₹0.67
+4.69%
GATECH reported a significant annual net profit increase of 265.04% for FY25, reaching ₹4 Cr, alongside an 81.82% revenue growth to ₹14 Cr. However, its latest quarterly net profit dropped by 26.4% YoY to ₹1 Cr, despite a 4.92% revenue increase to ₹4 Cr. The company's PE is 9.43 with ROCE at 16.43%, while its FCF remains negative at -₹23 Cr.
MODISO
82
MODISONLTD
Industrials
₹289.00
-1.57%
Modison Ltd. has delivered exceptional growth, with Q4 net profit skyrocketing 277.66% YoY to ₹36 Cr and annual net profit up 193.88% YoY to ₹73 Cr. Despite a recent price dip of 13.3% in the last month, its price has nearly doubled in the past three months (+96.65%), indicating strong market interest and positive sentiment driven by its operational efficiency reflected in a 25.31% OPM.
SATIN
82
SATIN
Financial Services
₹252.00
+2.44%
Satin Creditcare Network (SATIN) has seen its net profit jump by 640.16% YoY in Q4 2026, contributing to a TTM EPS of ₹30.2. Despite this strong performance, the stock trades at a TTM P/E of 8.49 and a P/B of 0.98, while its share price has risen 71.98% over the past three months and is currently -1.95% off its 52-week high.
CALSOF
82
CALSOFT
Technology
₹22.15
+2.07%
Calsoft's impressive Q4 2026 results show revenue growth of +605.02% YoY and net profit soaring +3012.49% YoY, leading to a TTM PE of 12.86. However, ML predictions indicate a weak outlook for Free Cash Flow (FCF) growth, with significant compression forecasted across all horizons (h1=-48.2%, h2=-50.0%, h3=-50.0%), raising questions about sustained profitability despite current strong performance.
VENUSR
80
VENUSREM
Healthcare
₹1686.80
-5.16%
Venus Remedies posted a strong Q1 2026, with net profit surging by 139.27% YoY to ₹23 Cr and revenue increasing by 35.6% YoY to ₹179 Cr. This robust performance comes despite ML predictions indicating a weak forecast for free cash flow (FCF), with a 1-year rolling 4-year FCF rank of 0.0. The stock has seen significant price appreciation, up 253.03% over the last year, while FIIs increased their holding by 0.12% QoQ.
Browse by sector
Regulatory disclosure: AI-generated research cards on this site are for educational and research purposes only. ftInvstr is not a SEBI-registered investment adviser or research analyst. Past performance does not guarantee future results. Consult a SEBI-registered adviser before making any investment decision.